US · BCYC · BIOTECHNOLOGY
Bicycle Therapeutics plc (BCYC) intrinsic value and stock valuation
$2.90as of 2026-11-21 · Mkt cap 275.5M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Bicycle Therapeutics plc DCF and intrinsic value
InvestorsCraft values BCYC with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from BCYC’s statements →
Bicycle Therapeutics plc Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2016–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Lexicon Pharmaceuticals, Inc. (LXRX) $1.53
- Omeros Corporation (OMER) $13.21
- 4D Molecular Therapeutics, Inc. (FDMT) $10.23
- Prothena Corporation plc (PRTA) $8.22
- Compass Therapeutics, Inc. (CMPX) $0.69
- Neumora Therapeutics, Inc. Common Stock (NMRA) $0.33
- Fulcrum Therapeutics, Inc. (FULC) $3.69
- ADC Therapeutics S.A. (ADCT) $1.28
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $72.6M | $35.3M | $27M | $14.5M | $11.7M |
| Operating income | -$-247.72M | -$-209.87M | -$-189.95M | -$-116.65M | -$-65.62M |
| Net income | -$-218.96M | -$-169.03M | -$-180.66M | -$-112.72M | -$-66.82M |
| EPSd | -$-3.16M | -$-2.9M | -$-5.08M | -$-3.8M | -$-2.67M |
| Operating cash flow | -$-249.68M | -$-164.72M | -$-60.63M | -$-86.11M | -$-14.79M |
| Capital expenditure | -$-2.36M | -$-1.24M | -$-2.93M | -$-18.99M | -$-2.03M |
| Free cash flow | -$-252.61M | -$-165.96M | -$-63.56M | -$-105.1M | -$-16.82M |
| Total assets | $717.6M | $956.9M | $595.3M | $410.6M | $479.8M |
| Total debt | $17.5M | $9.49M | $45M | $44.3M | $44.3M |
| Net debt | -$-610.59M | -$-870.03M | -$-481.47M | -$-294.83M | -$-394.34M |
| Total equity | $610M | $793.1M | $370.9M | $270.8M | $346.3M |
| Cash and short-term investments | $628.1M | $879.5M | $526.4M | $339.2M | $438.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $72.6M | $35.3M | $27M | $14.5M | $11.7M |
| Cost of revenue | $0.00 | $173M | $156.5M | $0.00 | $0.00 |
| Gross profit | $72.6M | -$-137.69M | -$-129.52M | $14.5M | $11.7M |
| Research and development expenses | $240.3M | $173M | $156.5M | $81.6M | $44.9M |
| Selling, general and administrative expenses | $80M | $71.5M | $59.8M | $49.5M | $32.4M |
| Other expenses | $0.00 | -$-172.25M | -$-155.9M | $0.00 | $0.00 |
| Operating expenses | $320.3M | $72.2M | $60.4M | $131.1M | $77.3M |
| Cost and expenses | $320.3M | $245.2M | $216.9M | $131.1M | $77.3M |
| Interest income | $28.5M | $34.3M | $14M | $5.76M | $120K |
| Interest expense | $210K | $1.73M | $3.26M | $3.34M | $2.98M |
| Depreciation and amortization | $6.42M | $7.18M | $6.55M | $3.69M | $1.41M |
| Ebitda | -$-212.18M | -$-164.89M | -$-169.4M | -$-107.21M | -$-64.09M |
| Operating income | -$-247.72M | -$-209.87M | -$-189.95M | -$-116.65M | -$-65.62M |
| Total other income/expenses, net | $28.9M | $36.1M | $10.7M | $2.41M | -$-2.86M |
| Income before tax | -$-218.81M | -$-173.8M | -$-179.21M | -$-114.24M | -$-68.48M |
| Income tax expense | $150K | -$-4.76M | $1.46M | -$-1.52M | -$-1.66M |
| Net income | -$-218.96M | -$-169.03M | -$-180.66M | -$-112.72M | -$-66.82M |
| Weighted average shares outstanding | $69.3M | $58.2M | $35.6M | $29.7M | $25.1M |
| Weighted average diluted shares outstanding | $69.3M | $58.2M | $35.6M | $29.7M | $25.1M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $628.1M | $879.5M | $526.4M | $339.2M | $438.7M |
| Net receivables | $35.6M | $35.7M | $24M | $21.2M | $11.9M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $682.9M | $928.6M | $561.9M | $369.4M | $458.6M |
| Property, plant and equipment, net | $21.9M | $17.2M | $27.7M | $32.8M | $17.8M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $60K | $550K | $550K | $0.00 | $0.00 |
| Total non-current assets | $34.7M | $28.3M | $33.5M | $41.2M | $21.2M |
| Total assets | $717.6M | $956.9M | $595.3M | $410.6M | $479.8M |
| Accounts payable | $9.67M | $15.8M | $13.1M | $6.47M | $2.72M |
| Short-term debt | $2.76M | $5.5M | $4.88M | $3.12M | $2.38M |
| Deferred revenue | $2.96M | $10.2M | $25M | $20.4M | $19.3M |
| Total current liabilities | $57M | $67.2M | $69.5M | $53.3M | $36.2M |
| Long-term debt | $14.8M | $3.99M | $40.1M | $41.2M | $42M |
| Deferred revenue, non-current | $35.5M | $91.5M | $110.2M | $41.5M | $52.1M |
| Total non-current liabilities | $50.6M | $96.6M | $154.9M | $86.5M | $97.3M |
| Capital lease obligations | $14.8M | $9.49M | $9.38M | $14M | $14.5M |
| Total liabilities | $107.6M | $163.8M | $224.4M | $139.8M | $133.5M |
| Common stock | $890K | $890K | $550K | $390K | $380K |
| Retained earnings | -$-899.75M | -$-680.79M | -$-511.76M | -$-331.1M | -$-218.38M |
| Accumulated other comprehensive income (loss) | -$-3.5M | $120K | -$-1.3M | $390K | -$-3.39M |
| Total equity | $610M | $793.1M | $370.9M | $270.8M | $346.3M |
| Total investments | $60K | $550K | $550K | $0.00 | $0.00 |
| Total debt | $17.5M | $9.49M | $45M | $44.3M | $44.3M |
| Net debt | -$-610.59M | -$-870.03M | -$-481.47M | -$-294.83M | -$-394.34M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-218.96M | -$-169.03M | -$-180.66M | -$-112.72M | -$-66.82M |
| Depreciation and amortization | $6.42M | $7.17M | $6.55M | $3.69M | $1.41M |
| Stock-based compensation | $39.5M | $38.1M | $32.5M | $26.8M | $12.1M |
| Change in working capital | -$-75.75M | -$-33.46M | $76.7M | $670K | $38.1M |
| Accounts receivable | $2.89M | -$-11.95M | -$-1.2M | -$-11.35M | $4.54M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | -$-4.79M |
| Accounts payable | -$-6.87M | $3.1M | $8M | $2.56M | $1.2M |
| Net cash provided by operating activities | -$-249.68M | -$-164.72M | -$-60.63M | -$-86.11M | -$-14.79M |
| Investments in property, plant and equipment | -$-2.36M | -$-1.24M | -$-2.93M | -$-18.99M | -$-2.03M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-2.35M | -$-1.24M | -$-2.93M | -$-18.99M | -$-2.03M |
| Common stock issued | $40K | $544.1M | $249.3M | $5.7M | $298.5M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-130K | $519.8M | $250M | $6.69M | $320.7M |
| Net change in cash | -$-251.35M | $353.1M | $187.8M | -$-99.53M | $302.7M |
| Cash at end of period | $628.7M | $880.1M | $527M | $339.2M | $438.7M |
| Operating cash flow | -$-249.68M | -$-164.72M | -$-60.63M | -$-86.11M | -$-14.79M |
| Capital expenditure | -$-2.36M | -$-1.24M | -$-2.93M | -$-18.99M | -$-2.03M |
| Free cash flow | -$-252.61M | -$-165.96M | -$-63.56M | -$-105.1M | -$-16.82M |
Line items
Line items
Line items
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in Phase I/II studies, which targets EphA2, and BT8009, currently in Phase I/II clinical development, designed to target Nectin-4. Beyond cancer, Bicycle Therapeutics is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase II clinical trials for the treatment of diabetic macular edema. Their portfolio also includes Bicycle tumor-targeted immune cell agonists (TICAs) such as BT7480, which targets Nectin-4, and BT7455, an EphA2/CD137 TICA presently in preclinical development. The company actively fosters collaborations with various biopharmaceutical entities and organizations, broadening its development efforts into therapeutic areas like anti-infectives, cardiovascular conditions, ophthalmology, and respiratory illnesses. Notable partnerships include a clinical trial and license agreement with Cancer Research Technology Limited and Cancer Research UK. They also maintain research collaborations with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund. Furthermore, a significant discovery collaboration and license agreement with Genentech is in place for the identification and development of Bicycle peptides for multiple immuno-oncology targets.
- CEO
- Kevin Lee
- Employees
- 288
- Beta
- 1.55
Explore
Frequently asked questions
What is the intrinsic value of Bicycle Therapeutics plc (BCYC)?
Bicycle Therapeutics plc (BCYC) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is BCYC undervalued?
BCYC trades at a price of $2.90 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.